ABVC BIOPHARMA INC (ABVC)
US00091F3047 - Common Stock
ABVC BIOPHARMA INC
NASDAQ:ABVC (9/27/2023, 7:09:48 PM)
After market: 1 0 (0%)1
+0.04 (+4.5%)
Company Profile
ABVC Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of drugs and medical devices derived from plants. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. The company has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, ABV-1703 and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1702 is used to treat myelodysplastic syndrome (MDS). ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. Its ABV-1519 is used for the treatment of non-small cell lung cancer.
Company Info
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA
P: 15106680881.0
CEO: Howard Doong
Employees: 19
Website: https://abvcpharma.com/
ABVC News
5 days ago - ChartmillFriday's session: top gainers and losersWhat's going on in today's session
9 days ago - ChartmillWondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
FREMONT, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical...
a month ago - NewMediaWireABVC BioPharma Provides Updates on ADHD Phase IIb Clinical StudySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
a month ago - NewMediaWireABVC Executes Cooperation Agreement for Strategic InvestmentsFREMONT, CA - (NewMediaWire) - August 17, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it had entered into a Cooperation Agreement to exchange a 20% ownership stake in real estate property of Zhonghui United Technology (Chengdu) Group Co., Ltd. (“中汇联和科技(成都)集团有限公司”) and its affiliated enterprises (“Zhonghui”).
FREMONT, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical...
ABVC Twits
Here you can normally see the latest stock twits on ABVC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
